Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC trimmed its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 25.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,802 shares of the biopharmaceutical company’s stock after selling 623 shares during the period. Virtus ETF Advisers LLC’s holdings in Xenon Pharmaceuticals were worth $71,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its stake in Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock valued at $95,000 after acquiring an additional 1,414 shares during the period. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $101,000. KBC Group NV lifted its stake in shares of Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 780 shares during the period. Magnetar Financial LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $210,000. Finally, HighMark Wealth Management LLC lifted its stake in shares of Xenon Pharmaceuticals by 22.0% in the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 1,100 shares during the period. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

XENE has been the subject of several analyst reports. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. The Goldman Sachs Group decreased their target price on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. StockNews.com upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, April 24th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $56.78.

Xenon Pharmaceuticals Stock Up 0.6 %

Xenon Pharmaceuticals stock opened at $37.84 on Tuesday. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $46.00. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -13.42 and a beta of 1.21. The company has a fifty day simple moving average of $34.79 and a 200-day simple moving average of $38.64.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.